We love to hear from our listeners. Send us a message.

Inspired to develop a treatment for Infantile Krabbe Disease, the founders of Forge Biologics picked a unique but strategic approach to funding the initiative. They built a CDMO that aims to become one of the largest on the planet in the cell and gene therapy space. On this week's episode of the Business of Biotech podcast, co-founder, President, & CEO Timothy J. Miller, Ph.D. joins us to discuss the strategy, why it was a no-brainer given the white-hot market for contract development and manufacturing space, the state of the biologics manufacturing capacity crunch,  and what companies like Forge are doing about it. 

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Subscribe to our monthly Business of Biotech newsletter.

Get in touch with guest and topic suggestions: [email protected]

Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/